Importantly, combined protease knockdown and PI3K-inhibitor treatment additionally impaired cell growth compared to the use of the PI3K-inhibitors alone, especially in human breast cancer cells and upon use of EC10. This evidence concerns the gene PIK3CA and breast carcinoma.